Evidence map›Paper›PMID 28665968›Full record

ArticlePloS one2017

High-dose thiamine prevents brain lesions and prolongs survival of Slc19a3-deficient mice.

Kaoru Suzuki, Kenichiro Yamada, Yayoi Fukuhara, Ai Tsuji, Katsumi Shibata, Nobuaki Wakamatsu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Can thiamine substitution restore cognitive function in alcohol use disorder?Alcohol and alcoholism (Oxford, Oxfordshire) · 2023
    Article
  6. Article
  7. Thiamine Deficiency Modulates p38Neurochemical research · 2020
    Article
  8. Article
  9. Article
  10. Amprolium exposure alters mice behavior and metabolism in vivo.Animal models and experimental medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kaoru SuzukiDepartment of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.
Kenichiro YamadaDepartment of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.
Yayoi FukuharaDepartment of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.
Ai TsujiDepartment of Nutrition, School of Human Cultures, The University of Shiga Prefecture, Hikone, Shiga, Japan.
Katsumi ShibataDepartment of Nutrition, School of Human Cultures, The University of Shiga Prefecture, Hikone, Shiga, Japan.
Nobuaki WakamatsuDepartment of Genetics, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.ORCID http://orcid.org/0000-0001-5693-2227
Aichi Human Service Center · JPUniversity of Shiga Prefecture · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SLC19A3 deficiency, also called thiamine metabolism dysfunction syndrome-2 (THMD2; OMIM 607483), is an autosomal recessive neurodegenerative disorder caused by mutations in SLC19A3, the gene encoding thiamine transporter 2. To investigate the molecular mechanisms of neurodegeneration in SLC19A3 deficiency and whether administration of high-dose thiamine prevents neurodegeneration, we generated homozygous Slc19a3 E314Q knock-in (KI) mice harboring the mutation corresponding to the human SLC19A3 E320Q, which is associated with the severe form of THMD2. Homozygous KI mice and previously reported homozygous Slc19a3 knock-out (KO) mice fed a thiamine-restricted diet (thiamine: 0.60 mg/100 g food) died within 30 and 12 days, respectively, with dramatically decreased thiamine concentration in the blood and brain, acute neurodegeneration, and astrogliosis in the submedial nucleus of the thalamus and ventral anterior-lateral complex of the thalamus. These findings may bear some features of thiamine-deficient mice generated by pyrithiamine injection and a thiamine-deficient diet, suggesting that the primary cause of THMD2 could be thiamine pyrophosphate (TPP) deficiency. Next, we analyzed the therapeutic effects of high-dose thiamine treatment. When the diet was reverted to a conventional diet (thiamine: 1.71 mg/100 g food) after thiamine restriction, all homozygous KO mice died. In contrast, when the diet was changed to a high-thiamine diet (thiamine: 8.50 mg/100 g food) after thiamine restriction, more than half of homozygous KO mice survived, without progression of brain lesions. Unexpectedly, when the high-thiamine diet of recovered mice was reverted to a conventional diet, some homozygous KO mice died. These results showed that acute neurodegeneration caused by thiamine deficiency is preventable in most parts, and prompt high-dose thiamine administration is critical for the treatment of THMD2. However, reduction of thiamine should be performed carefully to prevent recurrence after recovery of the disease.

Indexed as

AnimalsBrain DiseasesDose-Response Relationship, DrugHumansMembrane Transport ProteinsMiceMice, Inbred C57BLMice, KnockoutSurvival AnalysisThiamineThiamine DeficiencyMembrane Transport ProteinsSlc19a3 protein, mouseThiamine

Identifiers

PMID28665968
PMCPMC5493381
OpenAlexW2728697954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.